Different associations of tumor PIK3CA mutations and clinical outcomes according to aspirin use among women with metastatic hormone receptor positive breast cancer

Table 4 Odds of metastasis within 5 years of primary diagnosis

	N	%	Metastasis < 5 years
			Multivariate
			OR	95% CI	p-value
Age at Primary Dx
< 40	54	20.2	1	Reference
40–49	101	37.8	0.85	0.41–1.73	0.655
50–59	69	25.8	0.71	0.32–1.54	0.391
≥ 60	43	16.1	1.29	0.52–3.14	0.578
Stage at Primary Dx
1	62	23.2	1.00	Reference
2	131	49.1	1.38	0.72–2.64	0.321
3	59	22.1	2.93	1.34–6.37	0.007
Unknown	16	5.6	0.56	0.13–2.42	0.44
PR+	218	81.7	1.03	0.52–2.00	0.931
Grade
1	26	9.7	1.00	Reference
2	135	50.6	1.28	0.51–3.15	0.593
3	81	30.3	2.17	0.84–5.60	0.109
Unknown	25	9.4	0.44	0.11–1.65	0.222
Chemotherapy	214	80.1	1.08	0.55–2.11	0.826
PIK3CA mutated	97	36.3	0.71	0.41–1.22	0.213
Aspirin	54	20.2	1.31	0.67–2.55	0.421
p-interaction PIK3CA status & aspirin use					0.026
Aspirin non-user (N = 213)
PIK3CA mutated^a	213	79.8	0.51	0.27–0.94	0.032
Aspirin user (N = 54)
PIK3CA mutated^a	54	20.2	2.43	0.72–8.21	0.152

^aEstimates obtained from logistic model including interaction term for medication use and PIK3CA mutation status

ISSN: 1471-2407